- Home
- NXJ vs CLLS Comparison
NXJ vs CLLS Comparison
Compare NXJ & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXJ | CLLS |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 476.5M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | NXJ | CLLS |
|---|---|---|
| Price | $12.65 | $4.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 74.9K | ★ 115.5K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $10.06 | $1.10 |
| 52 Week High | $12.24 | $5.48 |
Technical Indicators
Market Signals| Indicator | NXJ | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | 54.54 |
| Support Level | $12.41 | $4.67 |
| Resistance Level | $12.73 | $5.10 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 63.13 | 57.79 |
Price Performance
Historical ComparisonAbout NXJ Nuveen New Jersey Qualified Municipal Fund
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.